Towards Healthcare
Cardiac Ablation Market to Lead USD 19.44 Bn by 2034

Cardiac Ablation Market Future Fueled by Tech and EP Demand

Market insights predict, the cardiac ablation industry is expected to grow from USD 5.15 billion in 2024 to USD 19.44 billion by 2034, driven by a CAGR of 14.24%. A global surge in minimally invasive approaches is propelling the global market. The growing AF prevalence is fueling North America's dominance.

Content

  • Insight Code: 6204
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The global cardiac ablation market size touched US$ 5.15 billion in 2024, with expectations of climbing to US$ 5.88 billion in 2025 and hitting US$ 19.44 billion by 2034, driven by a CAGR of 14.24% over the forecast period.

North America is currently leading the cardiac ablation market share by 40% due to a rise in AF incidences and the development of EP programs.

Some key players include Biosense Webster, Abbott Laboratories, Boston Scientific, Medtronic, and Philips Healthcare.

Key trends include the rising demand for minimally invasive approaches, growth in AI and other technologies, and innovations in ablation catheters.

VT ablation supports medication-resistant VT, managing ICD shocks, and improving quality of life.

NIH, US FDA, MedlinePlus.gov, ClinicalTrials.gov, CMS, CDC, GOV.UK, WHO.
Any Questions